Achieve Life Sciences Announces New Leadership
In an exciting development, Achieve Life Sciences, Inc. (NASDAQ: ACHV), a trailblazer in the specialty pharmaceutical sector, has appointed Dr. Mark Rubinstein as the Interim Chief Medical Officer (CMO). He takes over the role from Cindy Jacobs, Ph.D., M.D., who will continue to offer advisory services to the company. This transition comes as Achieve Life Sciences is poised to propel its efforts in advancing cytisinicline, a promising treatment for nicotine dependence.
Dr. Mark Rubinstein's Background
Dr. Rubinstein is a highly regarded veteran in the medical field, with extensive experience in clinical development and medical affairs. Before joining Achieve Life Sciences in October 2024 as Head of Medical Affairs, he served as the Head of Medical Affairs at Blip, where he played a pivotal role in developing strategies to help individuals quit smoking and vaping through FDA-approved therapies alongside digital support tools. His impressive career also includes a position as Vice President of Global Scientific Affairs at Juul Labs, where he was instrumental in initiatives aimed at reducing youth engagement with nicotine products. With an academic tenure spanning nearly two decades, Dr. Rubinstein was a Professor Emeritus at the University of California, San Francisco (UCSF). He is well-equipped for this new challenge, bringing valuable insights from his medical degree earned at Yale University and his internal medicine residency at Yale-New Haven Hospital.
Acknowledgment of Contributions
The CEO of Achieve Life Sciences, Rick Stewart, expressed gratitude to Cindy for her invaluable contributions, stating, "We thank Cindy for her many contributions and are pleased to appoint Mark to this critical role which is vital to our long-term success in addressing the nicotine dependence public health crisis." This change comes at a time when the company is making strides towards achieving FDA acceptance for their cytisinicline New Drug Application (NDA), with clinical, regulatory, and commercialization goals in place.
About Cytisinicline
Cytisinicline represents a potential breakthrough in smoking cessation efforts, addressing a dire public health challenge. Recent statistics highlight that there are around 29 million adults in the United States who smoke combustible cigarettes, making tobacco use the leading cause of preventable death globally. The numbers are staggering — tobacco claims more than eight million lives worldwide each year, including nearly half a million in the U.S. alone. Furthermore, more than 87% of lung cancer deaths and a significant portion of deaths from pulmonary diseases and heart disease are linked to smoking and secondhand smoke exposure.
Addressing Vaping Trends
Additionally, e-cigarette use has become a growing concern, with nearly 17 million adults in the U.S. using such products. Among the youth, approximately 1.6 million students reported using e-cigarettes in a recent survey. Despite the prevalence of these habits, there are currently no FDA-approved treatments specifically targeting nicotine e-cigarette cessation. Cytisinicline has received Breakthrough Therapy designation from the FDA, further emphasizing its importance in addressing this significant unmet need.
Mechanism of Action of Cytisinicline
This plant-derived alkaloid works by binding to the nicotinic acetylcholine receptor, which plays a critical role in reducing nicotine cravings and the satisfaction that individuals derive from nicotine use. As a result, cytisinicline aims not only to be a treatment for smoking cessation but also as a potential aid for e-cigarette cessation. It is still under investigation and has not received FDA approval for any indication in the United States yet.
Future Plans for Achieve Life Sciences
Looking ahead, Achieve Life Sciences remains optimistic about the future of cytisinicline and its role in treating nicotine dependence. The recent achievements in their NDA submissions and successful Phase 2 studies will likely play a significant role in shaping the company’s upcoming plans. Additionally, the ongoing advisory support from Dr. Jacobs will ensure a seamless transition and continued progress in their mission to combat nicotine dependence.
Frequently Asked Questions
What is Achieve Life Sciences, Inc. focused on?
Achieve Life Sciences is concentrated on developing and commercializing cytisinicline to treat nicotine dependence.
Who has been appointed as the Interim CMO?
Dr. Mark Rubinstein has been appointed as the Interim Chief Medical Officer.
What results has cytisinicline shown in studies?
Cytisinicline has shown promise in aiding smoking and vaping cessation through various clinical studies.
What is the significance of FDA acceptance for cytisinicline?
FDA acceptance is crucial as it indicates progress towards regulatory approval and potential commercialization of cytisinicline.
How is cytisinicline different from other nicotine cessation aids?
Cytisinicline is a plant-derived alkaloid that targets nicotine receptors, offering a novel approach in combating nicotine dependency.
